These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35201894)

  • 1. Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    Patel NA; Reiter RE
    J Clin Oncol; 2022 May; 40(13):1497-1499. PubMed ID: 35201894
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: 'Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    Guercio A; Franco G; Lombardo R; De Nunzio C
    BJU Int; 2024 Apr; 133 Suppl 4():23-24. PubMed ID: 38098312
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA; Burger IA
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
    J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
    Hussain M; Carducci MA; Clarke N; Fenton SE; Fizazi K; Gillessen S; Jacene H; Morris MJ; Saad F; Sartor O; Taplin ME; Vapiwala N; Williams S; Sweeney C
    J Clin Oncol; 2022 Sep; 40(26):3011-3014. PubMed ID: 35439030
    [No Abstract]   [Full Text] [Related]  

  • 6. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
    Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
    Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does
    Bianchi L; Schiavina R; Borghesi M; Ceci F; Angiolini A; Chessa F; Droghetti M; Bertaccini A; Manferrari F; Marcelli E; Cochetti G; Porreca A; Castellucci P; Fanti S; Brunocilla E
    Int J Urol; 2019 Aug; 26(8):804-811. PubMed ID: 31083784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
    Varatharajan A; Olivier T; Prasad V
    Eur Urol; 2023 Jun; 83(6):481-483. PubMed ID: 36774222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials.
    Smith CP; Xiang M; Armstrong WR; Nickols NG; Steinberg ML; Reiter RE; Rettig M; Weiner AB; Shen J; Valle L; Czernin J; Calais J; Kishan AU
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1079-1084. PubMed ID: 36863416
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?].
    Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T
    Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer.
    Hu C; Dong L; Xue W; Pienta KJ
    PET Clin; 2022 Oct; 17(4):555-564. PubMed ID: 36153235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.
    Andrews JR; Sood A; Chapin BF
    J Urol; 2023 Aug; 210(2):242-243. PubMed ID: 37194136
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case of the Season: Prostate Specific Membrane Antigen (PSMA) Positron-Emission Tomography (PET)-MRI to Evaluate Neoadjuvant Radiation Therapy Response.
    Chen C; Margolis DJ
    Semin Roentgenol; 2021 Oct; 56(4):363-365. PubMed ID: 34688338
    [No Abstract]   [Full Text] [Related]  

  • 17. How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
    Ptasznik G; Kelly BD; Murphy D; Lawrentschuk N; Kasivisvanathan V; Page M; Ong S; Moon D
    BJU Int; 2024 Feb; 133 Suppl 3():13-14. PubMed ID: 37691457
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma.
    Hoffmann MA; Buchholz HG; Wieler HJ; Müller-Hübenthal J; Trampert L; Richardsen I; Schreckenberger M
    Health Phys; 2020 Jul; 119(1):141-147. PubMed ID: 32301863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
    Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA
    Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.